Notably, CBM588 exhibited a positive impact on patients with NSCLC in the PD-L1 < 1% and PD-L1 1–49% groups but not in those with PD-L1 ≥ 50%. This evidence concerns the gene CD274 and non-small cell lung carcinoma.